Musgrave I F, Seifert R
Institut für Pharmakologie, Freie Universität Berlin, Germany.
Biochem Pharmacol. 1995 Jan 18;49(2):187-96. doi: 10.1016/s0006-2952(94)00432-3.
Human erythroleukaemia (HEL) cells were investigated to characterize their alpha 2-adrenoceptor and imidazoline receptor sites. Membranes from HEL cells bound [3H]2-(2-methoxy-1, 4-benzodioxan-2yl)-2-imidazoline ([3H]RX821002) in a saturable and specific manner with a KD of 0.64 +/- 0.07 nM and a Bmax of 126 +/- 4 fmol/mg protein. [3H]RX821002 was displaced from HEL membranes by adrenergic drugs with the order of potency being yohimbine approximately oxymetazoline >> prazosin = 2-[2-[4-(o-methoxyphenyl)piperazin-1-yl]ethyl]-4,4-dimethyl- 1,3(2H,4H)-isochinolindione HCl (ARC 239), consistent with this site being an alpha 2A-adrenoceptor. HEL membranes also bound [3H]idazoxan in the presence of adrenaline to block alpha 2-adrenoceptors. This binding was saturable and specific with a KD of 3.5 +/- 1.0 nM and a Bmax of 31 +/- 6 fmol/mg protein. Adrenergic drugs from both the phenylethylamine and imidazoline classes increased high-affinity GTPase activity, an index of activation of regulatory heterotrimeric guanine-nucleotide binding proteins (G-proteins), and produced increases in cytosolic free calcium concentration ([Ca2+]i). The effects of these agonists in both systems were abolished by pertussis toxin pretreatment, and oxymetazoline and clonidine were antagonists. The potency of adrenergic drugs to inhibit 5-bromo-6-(2-imidazolin-2-ylamino)-quinoxaline (UK 14304)-induced increases in [Ca2+]i was yohimbine approximately oxymetazoline >> ARC 239, consistent with the binding data and an action at alpha 2A-adrenoceptors. No evidence was found for a role of imidazoline receptors in stimulating G-proteins or modulating [Ca2+]i. The adrenergic agonist-induced increases in [Ca2+]i were due to both release of Ca2+ from intracellular stores and entry of extracellular Ca2+. Ca2+ entry was blocked by 1-(beta-[3-(4-methoxyphenyl)propoxy]-4-methoxyphenylethyl)-1H- imidazole hydrochloride (SKF 96365), but not by nitrendipine. Adrenaline also stimulated Mn2+ entry in HEL cells. Taken together, these results suggest that HEL cells have alpha 2A-adrenoceptors that activate non-selective cation channels via pertussis toxin-sensitive G-proteins, i.e. Gi-proteins.
对人红白血病(HEL)细胞进行了研究,以表征其α2 -肾上腺素能受体和咪唑啉受体位点。HEL细胞膜以饱和且特异的方式结合[3H]2 -(2 -甲氧基 - 1,4 -苯并二恶烷 - 2 -基)- 2 -咪唑啉([3H]RX821002),解离常数(KD)为0.64±0.07 nM,最大结合量(Bmax)为126±4 fmol/mg蛋白。肾上腺素能药物可将[3H]RX821002从HEL细胞膜上置换下来,其效力顺序为育亨宾≈羟甲唑啉>>哌唑嗪 = 2 - [2 - [4 -(邻甲氧基苯基)哌嗪 - 1 -基]乙基] - 4,4 -二甲基 - 1,3(2H,4H)-异喹啉二酮盐酸盐(ARC 239),这表明该位点是α2A -肾上腺素能受体。在肾上腺素存在的情况下,HEL细胞膜也结合[3H]咪唑克生以阻断α2 -肾上腺素能受体。这种结合是饱和且特异的,KD为3.5±1.0 nM,Bmax为31±6 fmol/mg蛋白。苯乙胺类和咪唑啉类的肾上腺素能药物均增加了高亲和力GTP酶活性,这是调节性异三聚体鸟嘌呤核苷酸结合蛋白(G蛋白)激活的一个指标,并导致胞质游离钙浓度([Ca2+]i)升高。百日咳毒素预处理可消除这些激动剂在两个系统中的作用,且羟甲唑啉和可乐定是拮抗剂。肾上腺素能药物抑制5 -溴 - 6 -(2 -咪唑啉 - 2 -基氨基)-喹喔啉(UK 14304)诱导的[Ca2+]i升高的效力顺序为育亨宾≈羟甲唑啉>> ARC 239,这与结合数据以及在α2A -肾上腺素能受体上起作用一致。未发现咪唑啉受体在刺激G蛋白或调节[Ca2+]i方面发挥作用的证据。肾上腺素能激动剂诱导的[Ca2+]i升高是由于细胞内钙库释放Ca2+以及细胞外Ca2+内流所致。Ca2+内流被1 -(β - [3 -(4 -甲氧基苯基)丙氧基] - 4 -甲氧基苯乙基)- 1H -咪唑盐酸盐(SKF 96365)阻断,但未被尼群地平阻断。肾上腺素还刺激了HEL细胞中的Mn2+内流。综上所述,这些结果表明HEL细胞具有α